Articles tagged with Serotonin Receptor Signaling
Researchers at UC Davis have developed a new method to create psychoactive-like molecules that mimic the brain's serotonin receptors. The study found five compounds with efficacy ranging from 61% to 93%, but none induced hallucinogenic behavior, offering a potential new therapeutic scaffold for treating psychiatric disorders.
Scientists found that activating specific neurons in the claustrum region of male rats under psychedelic exposure strengthens connections to areas implicated in psychiatric diseases, potentially explaining how psychedelics improve memory and symptoms. The study suggests a new pathway for understanding psychedelics' therapeutic effects.
Research synthesizes current evidence on psychedelic therapy's potential to fundamentally alter treatment paradigms for depression, anxiety, and PTSD. Chronic stress contributes significantly to psychiatric illness worldwide, leaving traditional treatments with residual symptoms or side effects.
Researchers found that Prozac's impact on mood behaviors is critical to the timing of its administration, with early postnatal exposure leading to increased anxiety- and depression-like behaviors, while adolescent exposure had the opposite effect. This study provides crucial mechanistic insights into alterations in neurocircuits that r...
Researchers identified how the brain assigns positivity or negativity to social experiences through a complex neural circuitry involving the hippocampus. They discovered that serotonin and neurotensin release opposing signals in the ventral CA1 region, which can be leveraged for future therapies.
A University of Ottawa-led study reveals that serotonin neurons are connected and interact with each other, controlling serotonin release in specific regions of the brain. This complex system has implications for understanding decision-making and developing targeted therapeutics for mood disorders.
A new review synthesizes evidence from molecular studies, animal research, and human trials to understand how ayahuasca influences emotional processing and memory systems. Key findings include ayahuasca's dual action through serotonin receptor types 5-HT2A and 5-HT1A.
Researchers discover 5-HT2A receptor selectively suppresses visual information strength without inhibiting parallel processes. This mechanism regulates the importance attached to incoming information, which could help develop new therapies for psychiatric diseases.
Researchers have found that the serotonin 2C receptor plays a crucial role in regulating memory in both mice and humans. The study discovered that non-functional mutations of the receptor are associated with memory deficits in humans, and that administering a serotonin analog can improve memory in animal models of Alzheimer's disease.
A new study has identified two proteins that play a vital role in modulating cell responses in schizophrenia. The researchers found that these proteins can be targeted to develop drugs that address specific symptoms of the disease, potentially leading to more effective and personalized treatments.
Researchers have shed light on the mechanisms by which psychedelic drugs, such as LSD and psilocybin, bind to and activate serotonin receptors. The study highlights the potential therapeutic benefits of these compounds in treating depression and anxiety disorders.
Scientists at Medical College of Wisconsin create biased agonists that reduce hallucinogenic effects while preserving therapeutic potential. These compounds, designed to selectively activate serotonin receptors, show promise in treating depression and other mental health conditions.
A new study found that the serotonin booster prucalopride increased functional brain connectivity in healthy adults, particularly between cognitive networks. The results suggest that prucalopride may improve cognitive function and have therapeutic potential for depression patients.
Researchers found altered serotonin 2A/C receptor binding in brain stems of infants who died from SIDS, suggesting a biological basis for the condition. The study suggests that specific combinations of genetic vulnerability, external stressors, and critical developmental periods may contribute to SIDS.
Researchers at UC Davis found that engaging serotonin 2A receptors inside neurons promotes growth of new connections, while the same receptors on cell surfaces do not. This discovery guides efforts to develop new treatments for depression and PTSD.
Researchers at Hokkaido University identify a nerve pathway in the brain stem involved in processing rewarding and distressing stimuli, opposing a previously identified pathway. This finding could lead to developing drug treatments for mental disorders like addiction and major depression.
A Baylor College of Medicine study reveals a connection between the serotonin 2C receptor and obesity, as well as maladaptive behaviors. The research findings suggest that rare mutations in the gene responsible for this receptor play a role in these conditions.
Researchers found reduced serotonin release capacity in individuals with depression, suggesting a blunted serotonin system. The study used novel imaging techniques to measure serotonin levels in the brain, providing crucial insights into the pathology of depression.
Researchers found that genetic variations in the serotonin 5-HT2A receptor impact its interaction with psychedelic drugs. Seven variants uniquely altered the receptor's response to psilocin, LSD, 5-MeO-DMT, and mescaline.
Researchers developed a new cancer therapy combining sulforaphane (SFN) and acetazolamide (AZ), which inhibits the PI3K/Akt/mTOR survival pathway and reduces 5-HT secretion in carcinoid syndrome. The combination therapy induces apoptosis in tumor cells, upregulates the p21 cell cycle inhibitor, and downregulates the PI3K/Akt/mTOR pathway.
The study found that phospholipid PtdIns4P and cholesterol play a critical role in G-protein coupling and ligand recognition, stabilizing the receptor's basal activity. Water molecules also mimic polar functionalities of serotonin, sustaining basal activity.
A team of scientists has developed a new analysis scheme to model dynamic cascading failures in power grids, taking into account the specific network dynamics between individual failures. This approach predicts potentially endangered lines and network components, enabling proactive risk assessments and system planning.
Researchers at UTSW Medical Center identified a cellular receptor central to the undesirable effects of antipsychotic drugs, which are essential medications for millions worldwide. Co-treating with a weight-loss drug that targets the serotonin 2c receptor prevented weight gain and improved metabolic profiles in mice.
Researchers elucidated the first ever computer simulation of a notoriously elusive serotonin receptor involved in fast signal transmission and various disorders. The discovery reveals how serotonin binds to the receptor, opening its ion channel's gate and transmitting electrical signals.
Researchers at the University of Helsinki have found a genetic mutation that renders carriers susceptible to impulsive and reckless behavior when drunk. The study, led by Dr. Roope Tikkanen, discovered a point mutation in the serotonin 2B receptor gene associated with increased impulsivity, particularly in response to alcohol consumption.
Researchers discovered that combining Roux-en-Y gastric bypass with specific medication can augment weight loss benefits. The study found independent pathways contributing to weight loss, suggesting potential for combination treatment.
A team of researchers from the University of Texas Medical Branch at Galveston and the University of Houston has found a new way to influence the vital serotonin signaling system. They have linked malfunctions in this system to various health issues, including depression, addictions, epilepsy, obesity, eating disorders, and more.
Scientists at University of Western Ontario discovered a biological link between stress, anxiety, and depression by identifying the connecting mechanism in the brain. A small molecule inhibitor was developed to selectively target depression and treat it more effectively.
Researchers found that manipulating serotonin receptors can block L-DOPA-induced side effects in advanced Parkinson's disease. The discovery suggests a new approach for developing treatments for this disorder, which is the second most common neurodegenerative disease after Alzheimer's.
Researchers found that a low dose of m-chlorophenylpiperazine (mCPP) improves glucose tolerance and lowers insulin levels in obese and diabetic mice. The drug works by stimulating a-melanocyte-stimulating hormone receptors, which is important for appetite control.
The Vanderbilt Conte Center for Neuroscience Research will investigate the role of serotonin in brain development and function, seeking to understand genetic variability's impact on mental health. The center aims to translate laboratory discoveries into improved treatments for mental illnesses, including depression and autism.
Researchers found extensive medullary serotonin pathway abnormalities in SIDS cases, involving multiple elements of serotonin function. These abnormalities may compromise protective reflexes, increasing the risk of SIDS, particularly in prone or face-down positions.
Researchers found a significant association between genetic variation and treatment outcome for antidepressant medication. Patients with the AA gene type were 16-18% more likely to benefit from citalopram, suggesting a key role of the serotonin 2A receptor in mechanism of action.
A new study suggests that middle-aged mice burn fewer calories during exercise, contributing to weight gain. The researchers identified the serotonin 5-HT(2c) receptor as a potential target for therapy.
Researchers investigated whether a specific serotonin transporter gene polymorphism is associated with psychosis and hallucinations in schizophrenia. Patients with the ll genotype had significantly higher ratings for psychosis and increased intensity of hallucinations compared to those with other genotypes.